Chimeric Therapeutics Limited (ASX:CHM)

Australia flag Australia · Delayed Price · Currency is AUD
0.0020
0.00 (0.00%)
Apr 21, 2026, 3:37 PM AEST
-99.60%
Market Cap 9.28M
Revenue (ttm) 9.75M
Net Income (ttm) -18.79M
Shares Out 44.19M
EPS (ttm) -0.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,502,000
Average Volume 15,451
Open 0.0020
Previous Close 0.0020
Day's Range 0.0010 - 0.0020
52-Week Range 0.0010 - 0.9000
Beta 0.85
RSI 53.33
Earnings Date May 28, 2026

About Chimeric Therapeutics

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treat... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol CHM
Full Company Profile

Financial Performance

In fiscal year 2025, Chimeric Therapeutics's revenue was 12.68 million, an increase of 70.09% compared to the previous year's 7.46 million. Losses were -10.43 million, -16.76% less than in 2024.

Financial Statements

News

There is no news available yet.